Breath Analysis in Lung Fibrosis
Completed
- Conditions
- Idiopathic Lung FibrosisIdiopathic Pulmonary Fibrosis
- Registration Number
- NCT02437448
- Lead Sponsor
- University of Zurich
- Brief Summary
The aim of the study is to answer the question whether a disease specific profile of breath in patients with idiopathic lung fibrosis can be detected by an untargeted metabolomic study using exhaled breath analysis by mass spectrometry.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 31
Inclusion Criteria
- Clinical symptoms consistent with IPF
- Age 40 through 80 years
- Diagnosis of UIP or IPF by HRCT and surgical lung biopsy as outlined in table 1. Only patients fulfilling the category "YES" will be included in the study.
- Extent of fibrotic changes (honeycombing, reticular changes) greater than extent of emphysema on HRCT scan
- No features supporting an alternative diagnosis
Exclusion Criteria
- Acute exacerbation within the last 6 weeks.
- Any relevant lung disease other than pulmonary fibrosis.
- Acute inflammatory disease (e.g. common cold) within the last 6 weeks.
- Acute or chronic hepatic disease.
- Renal failure or renal replacement therapy.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method IPF-specific mass spectrometric profile of volatile organic compounds of exhaled breath analysis (markers of IPF in exhaled breath) 1 day
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Can exhaled breath metabolomics identify unique molecular signatures in idiopathic pulmonary fibrosis (IPF) patients using SESI-MS technology?
How does secondary electrospray ionization mass spectrometry (SESI-MS) compare to traditional breath analysis methods in detecting IPF biomarkers?
What specific volatile organic compounds (VOCs) are associated with idiopathic lung fibrosis progression as identified by untargeted metabolomic studies?
Are there correlations between exhaled breath profiles and known IPF prognostic factors such as KL-6 or surfactant protein D levels?
How might breath analysis by SESI-MS influence non-invasive diagnostic strategies for interstitial lung diseases compared to current imaging techniques?
Trial Locations
- Locations (1)
Pulmonary Division, University Hospital of Zurich
🇨🇭Zurich, Switzerland
Pulmonary Division, University Hospital of Zurich🇨🇭Zurich, Switzerland